Skip to main content
. 2013 Oct 8;11:25. doi: 10.1186/1478-7547-11-25

Table 7.

Comparative chart of clinical and economic results for treatment of patients with hepatitis C genotype 1

Therapeutic schedule Total costs LY1 QALY2 Result
Peginterferon-alfa-2a + ribavirin
$Brz 31,185
14.51
12.89
peginterferon-alfa-2a is dominant
Peginterferon-alfa-2b + ribavirin $Brz 39,186 14.35 12.50  

Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.